Flotek Industries Inc FTK
We take great care to ensure that the data presented and summarized in this overview for FLOTEK INDUSTRIES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FTK
Top Purchases
Top Sells
About FTK
Flotek Industries, Inc. operates as a technology-driven chemistry and data company that serves customers across industrial, commercial, and consumer markets in the United States, the United Arab Emirates, and internationally. It operates in two segments, Chemistry Technologies (CT) and Data Analytics (DA). The CT segment designs, develops, manufactures, packages, distributes, delivers, and markets green specialty chemicals that enhance the profitability of hydrocarbon producers and cleans surfaces in commercial and personal settings to help reduce the spread of bacteria, viruses, and germs. This segment primarily serves integrated oil and gas, oilfield services, independent oil and gas, national and state-owned oil, geothermal energy, solar energy, and alternative energy companies. The DA segment designs, develops, produces, sells, and supports equipment and services that create and provide valuable information on the composition and properties of energy customers' hydrocarbon fluids. This segment's data platforms combine the energy industry's field-deployable, inline optical analyzer with proprietary cloud visualization and analytics. It sells its products directly through a mix of in-house sales professionals, as well as contractual agency agreements. The company was incorporated in 1985 and is headquartered in Houston, Texas.
Insider Transactions at FTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2025
|
Ryan Gillis Ezell CEO |
BUY
Grant, award, or other acquisition
|
Direct |
39,532
+16.02%
|
-
|
|
Nov 19
2025
|
James Bond Clement Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,969
+13.16%
|
-
|
|
Nov 13
2025
|
Harshavardhan V Agadi Director |
SELL
Open market or private sale
|
Direct |
66,956
-25.34%
|
$937,384
$14.71 P/Share
|
|
Oct 30
2025
|
Amy E. Blakeway SVP, GC and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,935
-9.23%
|
$70,830
$18.75 P/Share
|
|
Oct 30
2025
|
Amy E. Blakeway SVP, GC and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+20.47%
|
-
|
|
Oct 30
2025
|
Ryan Gillis Ezell CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,675
-5.79%
|
$354,150
$18.75 P/Share
|
|
Oct 30
2025
|
Ryan Gillis Ezell CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+14.32%
|
-
|
|
Oct 30
2025
|
James Bond Clement Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,838
-4.83%
|
$177,084
$18.75 P/Share
|
|
Oct 30
2025
|
James Bond Clement Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.35%
|
-
|
|
Aug 14
2025
|
Ryan Gillis Ezell CEO |
SELL
Open market or private sale
|
Direct |
87,187
-35.73%
|
$1,046,244
$12.26 P/Share
|
|
Aug 14
2025
|
Ryan Gillis Ezell CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
87,187
+15.65%
|
$435,935
$5.96 P/Share
|
|
Aug 14
2025
|
Ryan Gillis Ezell CEO |
SELL
Bona fide gift
|
Direct |
7,495
-4.56%
|
-
|
|
Aug 13
2025
|
James Bond Clement Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
45,732
-32.39%
|
$548,784
$12.74 P/Share
|
|
Aug 13
2025
|
James Bond Clement Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,732
+24.47%
|
$137,196
$3.28 P/Share
|
|
May 16
2025
|
Harshavardhan V Agadi Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,394
+2.36%
|
-
|
|
May 16
2025
|
Michael Fucci Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,394
+7.14%
|
-
|
|
May 16
2025
|
Lisa Mayr Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,394
+8.05%
|
-
|
|
May 16
2025
|
Evan R Farber Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,394
+9.5%
|
-
|
|
May 15
2025
|
Matthew Wilks |
BUY
Open market or private purchase
|
Indirect |
402
+0.25%
|
$5,628
$14.99 P/Share
|
|
May 14
2025
|
Matthew Wilks |
BUY
Open market or private purchase
|
Indirect |
13,040
+7.65%
|
$182,560
$14.15 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 83.1K shares |
|---|---|
| Open market or private purchase | 150K shares |
| Exercise of conversion of derivative security | 184K shares |
| Open market or private sale | 200K shares |
|---|---|
| Payment of exercise price or tax liability | 45K shares |
| Bona fide gift | 7.5K shares |